ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjogren Syndrome A Randomized Clinical Trial

He, Jing; Chen, Jiali; Miao, Miao; Zhang, Ruijun; Cheng, Gong; Wang, Yifan; Feng, Ruiling; Huang, Bo; Luan, Huijie; Jia, Yuan; Jin, Yuebo; Zhang, Xiaoying; Shao, Miao; Wang, Yu; Zhang, Xia; Li, Jing; Zhao, Xiaozhen; Wang, Han; Liu, Tian; Xiao, Xian; Zhang, Xuewu; Su, Yin; Mu, Rong; Ye, Hua; Li, Ru; Liu, Xu; Liu, Yanying; Li, Chun; Liu, Huixin; Hu, Fanlei; Guo, Jianping; Liu, Wanli; Zhang, Wen-Bin; Jacob, Alexander; Ambrus, Julian L., Jr.; Ding, Changhai; Yu, Di; Sun, Xiaolin*北京大学; 南方医科大学; 清华大学
JAMA Network Open2022-11-10DOI: 10.1001/jamanetworkopen.2022.41451
22被引3阅读
引用收藏
分享

摘要

IMPORTANCE Primary Sjogren syndrome (pSS) is a systemic autoimmune disease associated with dysregulated immune cells, with no efficient therapy. There is a need to study potential therapeutic approaches. @@@ OBJECTIVE To investigate the efficacy, safety, and immune response of low-dose interleukin 2 (LD-IL-2) in the treatment of pSS. @@@ DESIGN, SETTING, AND PARTICIPANTS A double-blind, placebo-controlled randomized clinical trial was conducted with a 2-group superiority design from June 2015 to August 2017. Sixty patients, aged 18 to 70 years. were recruited from Peking University People's Hospital. Efficacy analyses were based on the intention-to-treat (ITT) principle. Data were analyzed from December 2018 to March 2020. @@@ INTERVENTIONS Patients with pSS were treated with LD-IL-2 or placebo for 12 weeks and accompanied by 12 weeks of follow-up. @@@ MAIN OUTCOMES AND MEASURES The primary end point was defined as a 3-point or greater improvement on the European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) by week 24. The secondary end points included other clinical responses, safety, and changes of immune cell subsets at week 12 and 24. @@@ RESULTS Sixty patients with pSS were recruited, with 30 in the LD-IL-2 group (mean [SD] age, 47.6 [12.8] years; 30 [100%] women) and 30 in the placebo group (mean [SD] age, 51.0 [11.9] years; 30 [100%] women), and 57 completed the trial. More patients in the LD-IL-2 group (20 [66.7%]) achieved ESSDAI score reduction of at least 3 points than in the placebo group (8 [26.7%]) at week 24 (P = .004). There were greater resolutions of dryness, pain, and fatigue in the LD-IL-2 group than placebo group at week 12 (dryness: difference, -18.33 points; 95% CI. -2846 to -8.21 points; P = .001; pain: difference, -10.33 points; 95% CI, -19.38 to -1.29 points; P = .03; fatigue: difference, -11.67 points; 95% CI, -20.65 to -2.68 points; P = .01). No severe adverse events were observed in either group. In addition, the LD-IL-2 group showed a significant decrease in infection compared with the placebo group (1 [3.3%] vs 9 [30.0%];P = .006). Immunological analysis revealed that LD-IL-2 promoted an expansion of regulatory T cells and regulatory CD24(high)CD27(+). B cells. @@@ CONCLUSIONS AND RELEVANCE In this randomized clinical trial, LD-IL-2 was effective and well tolerated in patients with pSS, and it restored immune balance, with enhanced regulatory T cells and CD24(high)CD27(+) B cells.

学科与关键词

关键词
T-CELL RESPONSESPERIPHERAL-BLOODDOUBLE-BLINDIL-2CONSENSUSLYMPHOCYTESBAFF
相关
加载中…
  • Chinese herbal medicine SS-1 inhibits T cell activation and abrogates TH responses in Sjögren's syndrome
    Lee Gilbert Aaron; Chang Ching-Mao; Wu Ying Chieh; Ma Ruo-yu; Chen Cheng-Yu; Hsue Yin-Tzu; Liao Nan-Shih; Chang Hen-HongJournal of the Formosan Medical Association, 2021, 120(1P3).
  • Interferon alpha serum level association with low vitamin D levels in Chinese patients with primary Sjogren's syndrome
    Zheng, Muhan; Zhu, Shijie; Li, Yang; Chen, Jianhui; Lai, Weinan*European Journal of Inflammation, 2021, 19.被引 2
  • Single-Cell RNA Sequencing Reveals the Expansion of Cytotoxic CD4+ T Lymphocytes and a Landscape of Immune Cells in Primary Sjogren's Syndrome
    Hong, Xiaoping; Meng, Shuhui; Tang, Donge; Wang, Tingting; Ding, Liping; Yu, Haiyan; Li, Heng; Liu, Dongzhou; Dai, Yong*; Yang, Min*Frontiers in Immunology, 2021, 11: 594658.被引 47
查看全部 →

发表信息

论文状态
公开发表
期刊
JAMA Network Open
发表日期
2022-11-10
卷期
第 5 卷, 第 11 期
页码
e2241451
DOI
10.1001/jamanetworkopen.2022.41451
期刊等级
1区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [32141004, 82271835, 82071813, 81671602, 82171772, 81771743, 81871281, 82202003, U1903210]; Beijing Sci-Tech Program [Z191100006619110, Z191100006619114]; Macao Science and Technology Fund [0094/2018/A3]; Natural Science Foundation of Hunan [2022JJ40674]

作者

  • H

    He, Jing (第一作者)

    peking univ

  • C

    Chen, Jiali

    peking univ

查看全部 39 位作者收起作者
  • M

    Miao, Miao

    peking univ

  • Z

    Zhang, Ruijun

    peking univ

  • C

    Cheng, Gong

    peking univ

  • W

    Wang, Yifan

    peking univ

  • F

    Feng, Ruiling

    peking univ

  • H

    Huang, Bo

    peking univ

  • L

    Luan, Huijie

    peking univ

  • J

    Jia, Yuan

    peking univ

  • J

    Jin, Yuebo

    peking univ

  • Z

    Zhang, Xiaoying

  • S

    Shao, Miao

    peking univ

  • W

    Wang, Yu

    renmin univ china

  • Z

    Zhang, Xia

  • L

    Li, Jing

    peking univ

  • Z

    Zhao, Xiaozhen

    peking univ

  • W

    Wang, Han

    peking univ

  • L

    Liu, Tian

    peking univ

  • X

    Xiao, Xian

    peking univ

  • Z

    Zhang, Xuewu

    peking univ

  • S

    Su, Yin

    peking univ

  • M

    Mu, Rong

    peking univ

  • Y

    Ye, Hua

    peking univ

  • L

    Li, Ru

    peking univ

  • L

    Liu, Xu

    peking univ

  • L

    Liu, Yanying

    peking univ

  • L

    Li, Chun

    peking univ

  • L

    Liu, Huixin

    peking univ

  • H

    Hu, Fanlei

    peking univ

  • G

    Guo, Jianping

    peking univ

  • L

    Liu, Wanli

    tsinghua univ

  • Z

    Zhang, Wen-Bin

    peking univ

  • J

    Jacob, Alexander

  • A

    Ambrus, Julian L., Jr.

  • D

    Ding, Changhai

    southern med univ

  • Y

    Yu, Di

  • S

    Sun, Xiaolin (通讯)

    peking univ

  • L

    Li, Zhanguo (通讯)

    peking univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417